% | $
Quotes you view appear here for quick access.

NeuroMetrix Inc. Message Board

bernsteinjoshi 25 posts  |  Last Activity: May 1, 2015 3:46 AM Member since: Jun 12, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Aezs delist tomorrow

    by sell_part Apr 30, 2015 10:42 PM
    bernsteinjoshi bernsteinjoshi May 1, 2015 3:46 AM Flag

    they have time untill mid june to resolve the issue with potential to extend for another 3-6 months . CEO said Delisting will NOT happen so Reverse Split is an option to keep the Nasdaq listing . Next time you should do some dd before posting pure garbage .

  • Currently they have 24 ANDA´s under review by FDA these number will rise from 24 to 42 ANDA´s by year end ,
    IG is a very attractive stock at this bargain levels .GL

    Mr. Grenfell-Gardner continued, "These changes in the market dynamics of one product in the short term will not distract us from our dedication to the creation of long-term shareholder value through the execution of our TICO strategy to expand our presence in the topical, injectable, complex and ophthalmic markets. We still believe that 2015 is the year dedicated to building our foundation, focused on the advancement of our research and development pipeline. We believe that we are making good progress on the injectable and ophthalmic product projects, as well as our first 505(b)2 topical project, so we are actively pursuing all areas of our TICO strategy. As of today, we have twenty-four ANDAs pending with the FDA. Based on February 2015 IMS Health data, the addressable market for our pipeline of twenty-four ANDAs, pending approval by the FDA, is estimated at $702 million. Our team has now filed its first two ANDAs for 2015, and is on target to file at least another four in the second quarter of 2015. Including the products currently on stability, our team has almost doubled productivity over this time last year, and we expect to be on target to file 20 topical ANDA submissions in 2015."

    Sentiment: Strong Buy

  • quickly if there is no buyout by Gilead or Celgene . GBIM is still an undiscovered Stock with Brutal Upside Potential . The Market Cap of less than $50 Million is a joke .GL

    Sentiment: Strong Buy

  • Celgene is largest Shareholder who bought the shares at $10 . Very attractive Pipeline and Strong Insider & Institutional Ownership who holding almost 50% of the 5.7 M Shares Outstanding .

    Big and very important Phase 2 (Hepatitis B) partnered with Gilead coming in 2Q if positive then this low float monster could explode like BLUE or ESPR .

    Sentiment: Strong Buy

  • GBIM is the Cheapest Hepatitis Play you can get on the Stockmarket with a laughable Market Cap of $42 Million and $17 Million in Cash . GBIM is partnered with World Class Biotechs Gilead and Celgene and Celgene is the largest Shareholder of this undiscovered Goldmine . There are only 5.7 Million Shares Outstanding means if Phase 2 results are positive then this one will explode like a Nuclear bomb .GL

    GS-US-330-0101, or the 0101 trial, is a randomized Phase 2 clinical trial, initiated in 2013, investigating GS-4774 in combination with ongoing oral antiviral treatment in patients with chronic HBV infection. The 0101 trial is a multicenter, multinational trial that enrolled 175 patients in a randomized, open-label design comparing three different doses of GS-4774, administered in combination with oral antiviral therapy versus antiviral treatment alone. The primary endpoint for this trial is decline in serum HBV surface antigen, or HBsAg. The 0101 trial is fully-enrolled, and 48-week results are expected to be available in the first half of 2015. These results may be submitted to an upcoming scientific conference.

    We have two strategic collaborations with leading biotechnology companies. In October 2011, Gilead Sciences, Inc., or Gilead, exclusively licensed product candidates intended to treat chronic hepatitis B virus, or HBV, infection. Celgene Corporation, or Celgene, entered into a collaboration and option agreement for certain oncology product candidates in May 2009. Under this agreement, in July 2013 Celgene exercised its option for a worldwide, exclusive license to the GI-6300 program, which is a Tarmogen program targeting the brachyury protein. Brachyury plays a role in the metastatic progression of certain cancers and is believed to be fundamental in the formation of chordomas, rare bone tumors of the spine. Through March 31, 2014, we have received over $60 million from these collaborations.

    Sentiment: Strong Buy

  • bernsteinjoshi by bernsteinjoshi Mar 30, 2015 3:45 PM Flag

    Telesta is close to 52W high and its still brutally undervalued with a ridiculous Market Cap of around C$63 Million (US$ 49.6 Million) .

    Telesta Therapeutics – (TST on TSX) (BNHLF)

    Presentation Time - Wednesday April 1st – 11:40 AM ET

    Current Market Cap – Approx. $63 M

    Telesta is a late stage therapeutics company with near term commercial potential focused on a unique specialty drug (MCNA) for non-muscle invasive bladder cancer. The drug has completed a phase III study and the Company expects to file it biologics application license (BLA) with the FDA in Q2 of 2015.

    Additional Highlights

    The US FDA has reviewed the Company’s clinical data and is supportive of a BLA filing with no additional trials.

    MCNA is a high margin biologic opportunity for Telesta that will be priced as a premium oncology product. The market size has been validated by an independent 3rd party and this market is significant.

    The Company has very strong intellectual property coverage with a patent term that would expire in 2031 along with secondary protection of 12 years with US market exclusivity for novel biologic.

    There has not been a new treatment for this type of cancer approved by the FDA since 1998.


    Sentiment: Strong Buy

  • this junk will be in the sub pennies within 2-3 years

    Sentiment: Strong Sell

  • this garbage is wayyy overvalued should trade below $5

    Sentiment: Strong Sell

  • maybe institutions are buying before they let the stock run .

    Sentiment: Strong Buy

  • Dr. Jia Zhidan, General Manager of Sinopharm A-Think, similarly indicated that, “We believe zoptarelin doxorubicin can pioneer the use of conjugate technology in advanced endometrial cancer, as earlier clinical development with this product has shown encouraging data in overall survival and tolerability. We also believe that zoptarelin doxorubicin has the potential to become our star product in the future. As an enterprise committed to building up a professional anti-cancer platform, we would like to look for additional promising products such as zoptarelin doxorubicin, and are more than willing to cooperate with excellent companies such as Aeterna Zentaris. We hope to engage additional cooperation opportunities in the future, benefitting more cancer patients.”


    Sentiment: Strong Buy

  • bernsteinjoshi bernsteinjoshi Mar 16, 2015 12:02 PM Flag

    definitely a good stock to own nobody would invest millions of dollars if they dont see potential here

    Sentiment: Strong Buy

  • bernsteinjoshi bernsteinjoshi Mar 13, 2015 12:52 PM Flag

    Im a daytrader so its possible that i was in for a few hours , im trading 5-20 stocks per Week

    You say that im pumping this stock since 2013 and thats the lie .

  • bernsteinjoshi bernsteinjoshi Mar 13, 2015 12:15 PM Flag

    I shorted this stock a few years ago because of Missmanagement but i was never Long on this stock before . Again stop the lies

  • bernsteinjoshi bernsteinjoshi Mar 13, 2015 11:44 AM Flag

    stop it liar.. i bought this stock first time late last year because of the FDA decision of Macrilen

  • i like to be a bagholder here

    Sentiment: Buy

  • and just trading at Cash Level . Definitely worth the risk here .GL

    Sentiment: Strong Buy

  • This below is the best part of the earnings ..Major Partnership or Buyout is on the way and wewill see a Mega rally in the coming Weeks thats for sure . This juwel is still undiscovered and thats the main reason why we still tradng at this ridiculous low level ,this is definitely one of the cheapest Cancer Stock on the Stock Market .GL.


    •Under-the-radar Canadian public company with little/no exposure to
    U.S./Institutional investors

    US BLA submission targeted for Q2/2015 – potential approval in Q1/2016
    •De-risked through significant interaction with US FDA

    US peak market estimate $400 million with comparable market opportunity ex-US

    New and focused senior management team and board has transformed the

    •Unencumbered, late stage, near-commercial uro-oncology asset
    •Very favourable specialty pharma product profile
    •Patent protection potential to 2031
    •Strong competitive position – no late stage competition
    •Significant 3rd party interest in this asset

    The Company also reported that there is significant 3rd party interest in the MCNA program and that it is in receipt of multiple non-binding expressions of interest from a variety of public and private pharmaceutical and biotechnology companies. Due to the confidential nature of the ongoing discussions, Telesta will only provide further updates to shareholders upon signature of a binding agreement.

    Dr. Michael Berendt, CEO & Chief Scientist of Telesta cautioned that: "We will fully evaluate and negotiate the current offers to ensure that if we take the decision to partner MCNA or sell the company at this juncture, that such a decision will capture significant value for our investors."

    Sentiment: Strong Buy

  • If Phase 3 is really positive then this Stock will explode like KERX or ACAD did .GL

    Maxim Maintains Buy On Aeterna Zentaris Ahead Of Zoptarelin-Dox Data

    In a research report sent to investors today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (NASDAQ:AEZS) with a $2.00 price target, which implies an upside of 251% from current levels.

    Kolbert said, “Zoptarelin-Dox data (interim analysis) in 1H15 represents a key event for the company. We believe that the incremental improvements to this standard of care agent should make it a low risk, high probability of positive outcome event.”

    Zoptarelin Doxorubicin

    –Potentially the first FDA approved medical therapy for treating
    recurrent endometrial cancer

    Interim results in H1-2015 (~128 events)

    Significant Market Opportunity Potential

    Estimated Potential Annual Market Value
    Medical Therapy Treating Recurrent Endometrial Cancer

    North America $300–$400 Million

    Europe $150–$250 Million

    Sentiment: Strong Buy

  • thats all what they want

    Sentiment: Sell

  • bernsteinjoshi bernsteinjoshi Feb 10, 2015 2:07 PM Flag

    definitely a fanstatic short for the coming days

    Sentiment: Strong Sell

1.26+0.02(+1.55%)May 4 3:59 PMEDT